Related Experiment Video
Updated: May 16, 2026
12:25
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
Botulinum toxins for facial lines: a concise review
Nicholas J Lowe1, Philippa Lowe
1The Cranley Clinic, 3 Harcourt House, 19a Cavendish Square, London, W1G 0PN UK ; UCLA School of Medicine, Los Angeles, CA USA.
Dermatology and Therapy
|December 4, 2012
Summary
Botulinum toxins (BTX) are reviewed for dermatologic and cosmetic uses, including reducing wrinkles and hyperhidrosis. Research is exploring a topical BTX-A as a non-injectable alternative.
Area of Science:
- Dermatology
- Cosmetic Procedures
- Neuromodulation
Background:
- Botulinum toxins (BTX) were initially developed to treat strabismus and blepharospasm by targeting ocular muscle activity.
- The cosmetic application of BTX type A (BTX-A) emerged serendipitously from observations in patients treated for blepharospasm, noting a reduction in forehead lines.
- Over 40 years of clinical research have established BTX's role beyond its initial therapeutic indications.
Purpose of the Study:
- To provide a clinical review of the established and emerging applications of botulinum toxins in dermatology and aesthetic medicine.
- To highlight the transition of BTX from treating neuromuscular disorders to cosmetic facial rejuvenation and other dermatologic conditions.
- To discuss the ongoing development of novel delivery methods for BTX.
Main Methods:
- This review synthesizes existing clinical data and research findings on botulinum toxin applications.
- It focuses on the clinical efficacy and observational outcomes rather than basic science or pharmacology.
- The review examines the evolution of BTX usage from ophthalmology to broader dermatologic and cosmetic fields.
Main Results:
- Botulinum toxin type A (BTX-A) is widely used for aesthetic purposes, effectively reducing hyperfunctional facial muscles responsible for wrinkles.
- BTX is also a recognized treatment for localized hyperhidrosis, offering significant relief for affected individuals.
- Clinical development is underway for a topical formulation of BTX-A, aiming to provide a non-invasive treatment option.
Conclusions:
- Botulinum toxins have evolved into versatile agents in dermatology and cosmetic procedures, with BTX-A being a prominent example.
- The established efficacy in treating wrinkles and hyperhidrosis, coupled with ongoing innovation in delivery systems, ensures a continuing role for BTX.
- Future developments, such as topical BTX-A, promise to expand treatment accessibility and patient options in aesthetic dermatology.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:14Muscles for Facial Expressions
The craniofacial muscles are a collection of approximately 20 thin skeletal muscles situated beneath the skin of the face and scalp. These muscles, primarily responsible for the vast array of human facial expressions, originate from the bones or fibrous structures of the skull and extend outwards to connect with the skin. While most skeletal muscles in the body are enveloped in thick fascia, facial muscles generally have a more delicate fascial covering, with the buccinator muscle being a...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...